Screener
Exagen Inc. XGN EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Exagen Inc. in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The source filing: Exagen Inc.’s 10-Q, filed May 11, 2026.
- Filed
- May 11, 2026, 9:17 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001274737-26-000029
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Interest expense | (1,267) | (545) |
| Change in fair value of warrant liability | 882 | — |
| Other income (expense), net | (132) | 158 |
| Loss before income taxes | (3,931) | (3,752) |
| Income tax expense | (36) | — |
| Net loss | $(3,967) | $(3,752) |
| Net loss per share, basic and diluted | $(0.17) | $(0.20) |
| Weighted-average number of shares used to compute net loss per share, basic and diluted | 23,854,997 | 18,557,390 |
Item 1. Financial Statements
FAQ
- What is Exagen Inc.'s EPS (diluted)?
- Exagen Inc. (XGN) reported EPS (diluted) of -$0.17 in Q1 2026.
- How has Exagen Inc.'s EPS (diluted) changed year-over-year?
- Exagen Inc.'s EPS (diluted) increased by 15.0% year-over-year, from -$0.20 to -$0.17.
- What is the long-term trend for Exagen Inc.'s EPS (diluted)?
- Over 4 years (2021 to 2025), Exagen Inc.'s EPS (diluted) has grown at a -14.1% compound annual growth rate (CAGR), from -$1.69 to -$0.92.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.
Ask your AI about Exagen Inc.'s eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude